About Us

ZERION has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and the therapeutic options for patients. The Dispersome® technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin. ZERION develops proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. The Dispersome® technology is patent protected and offers in connection with any pharmaceutical drug many additional years of IP protection. ZERION was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research. (Dispersome® is a trademark of Zerion Pharma A/S)